Compare BridgeBio Pharma Inc (BBIO) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nokia Corp — how do they compare? BridgeBio Pharma Inc trades at $83.81 (market cap $16.36B), while Nokia Corp trades at $10.21 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 3.2× BridgeBio Pharma Inc's market cap, and Nokia Corp pays a 1.73% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NOK | |
|---|---|---|
Market Cap | $16.36B | $53.00B |
Sector | Health | Technology |
52-Week High | $90.17 | $16.83 |
52-Week Low | $47.29 | $4.13 |
Enterprise Value | $18.14B | $50.95B |
Dividend Yield | — | 1.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
